Interstitial lung disease associated to erlotinib treatment: a case report
نویسندگان
چکیده
INTRODUCTION Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described. CASE PRESENTATION We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease. CONCLUSION Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.
منابع مشابه
Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature
Erlotinib is one of the most widely used tyrosine kinase inhibitor targeting human epidermal growth factor receptor. Since its introduction, it has revolutionized the treatment of advanced non-small cell lung cancer. Skin rashes and diarrhea are the most often reported side effects of erlotinib however it is also associated with interstitial pneumonitis or interstitial lung disease, which often...
متن کاملErlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategies. We report a case of severe ILD in a non-small cell lung cancer patient treated with gefitinib...
متن کاملErlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
Erlotinib (Tarceva) is a human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Interstitial lung disease, associated with gefitinib (Iressa) use, has been reported in approximately 1% of patients worldwide. However, the adverse pulmo...
متن کاملa 2.5 months old girl with interstitial lung disease-a case report
Children interstitial lung (ChILD) disease is a large group of disorders with damage in alveolus and capillary. Although these disorders resemble ILD of adult in nomination, ChILD represents different pathologic and clinical patterns. A 2.5 months old girl, with failure to thrive and grunting and dyspnea, complained of staccato coughs without association with feeding, since she was 15 days o...
متن کاملBoth gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while many studies have reported on gefitinib-related interstitial lung disease (ILD), less published data are available regarding erlotinib-induced ILD. Here, we report a case of pulmonary adenocarcinoma who developed ILD due to gefitinib initially and erlotinib thereafter. The two episodes of ILD we...
متن کامل